AQR Capital Management
ADVM

AQR Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

AQR Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-33,823
Closed -$148K – 3293
2025
Q1 		$148K Buy
+33,823
New +$152K ﹤0.01% 2945
2024
Q4 		– Sell
-59,970
Closed -$421K – 2864
2024
Q3 		$421K Buy
+59,970
New +$435K ﹤0.01% 2247
2021
Q1 		– Sell
-2,157
Closed -$234K – 2179
2020
Q4 		$234K Sell
2,157
-4,431
-67% -$548K ﹤0.01% 2042
2020
Q3 		$679K Sell
6,588
-2,344
-26% -$351K ﹤0.01% 1602
2020
Q2 		$1.86M Sell
8,932
-8,811
-50% -$1.56M ﹤0.01% 1183
2020
Q1 		$1.73M Buy
17,743
+13,876
+359% +$1.62M ﹤0.01% 1126
2019
Q4 		$445K Buy
3,867
+955
+33% +$84.2K ﹤0.01% 1786
2019
Q3 		$159K Buy
2,912
+486
+20% +$54.8K ﹤0.01% 2043
2019
Q2 		$288K Sell
2,426
-1,033
-30% -$85.5K ﹤0.01% 1891
2019
Q1 		$181K Sell
3,459
-4,280
-55% -$173K ﹤0.01% 2090
2018
Q4 		$244K Sell
7,739
-6,169
-44% -$251K ﹤0.01% 2028
2018
Q3 		$841K Buy
13,908
+10,431
+300% +$586K ﹤0.01% 1767
2018
Q2 		$184K Buy
+3,477
New +$209K ﹤0.01% 2234
2016
Q3 		– Sell
-12,395
Closed -$392K – 2245
2016
Q2 		$392K Buy
12,395
+1,922
+18% +$86.8K ﹤0.01% 1948
2016
Q1 		$541K Sell
10,473
-203
-2% -$11.3K ﹤0.01% 1807
2015
Q4 		$1.02M Buy
+10,676
New +$938K ﹤0.01% 1563

Other funds holding ADVM

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management's ADVM Position: Q2 2025 in Review

AQR Capital Management sold out of Adverum Biotechnologies (ADVM) in Q2 2025, closing a stake of 33,823 shares — an estimated $148K sold.

AQR Capital Management first reported a position in ADVM in Q4 2015 and held it in 16 quarters. The position peaked at $1.86M in Q2 2020. 58 funds tracked by Wall St. Rank hold ADVM as of Q2 2025.

  • AQR Capital Management reported no remaining Adverum Biotechnologies position as of Q2 2025 after selling out during the quarter.
  • AQR Capital Management sold 33,823 Adverum Biotechnologies shares in Q2 2025, an estimated $148K.
  • AQR Capital Management first reported a position in Adverum Biotechnologies in Q4 2015 and held it in 16 quarters.
  • AQR Capital Management's Adverum Biotechnologies position peaked at $1.86M in Q2 2020.
  • 58 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2025.

Based on AQR Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.